A treatment for and vaccine against the deadly Hendra and Nipah viruses

Christopher C. Broder, Kai Xu, Dimitar B. Nikolov, Zhongyu Zhu, Dimiter S. Dimitrov, Deborah Middleton, Jackie Pallister, Thomas Geisbert, Katharine N. Bossart, Lin Fa Wang

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Hendra virus and Nipah virus are bat-borne paramyxoviruses that are the prototypic members of the genus Henipavirus. The henipaviruses emerged in the 1990s, spilling over from their natural bat hosts and causing serious disease outbreaks in humans and livestock. Hendra virus emerged in Australia and since 1994 there have been 7 human infections with 4 case fatalities. Nipah virus first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India. In total, there have been an estimated 582 human cases of Nipah virus and of these, 54% were fatal. Their broad species tropism and ability to cause fatal respiratory and/or neurologic disease in humans and animals make them important transboundary biological threats. Recent experimental findings in animals have demonstrated that a human monoclonal antibody targeting the viral G glycoprotein is an effective post-exposure treatment against Hendra and Nipah virus infection. In addition, a subunit vaccine based on the G glycoprotein of Hendra virus affords protection against Hendra and Nipah virus challenge. The vaccine has been developed for use in horses in Australia and is the first vaccine against a Biosafety Level-4 (BSL-4) agent to be licensed and commercially deployed. Together, these advances offer viable approaches to address Hendra and Nipah virus infection of livestock and people.

Original languageEnglish (US)
Pages (from-to)8-13
Number of pages6
JournalAntiviral Research
Volume100
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Hendra Virus
Nipah Virus
Vaccines
Henipavirus
Livestock
Virus Diseases
Disease Outbreaks
Glycoproteins
Subunit Vaccines
Tropism
Bangladesh
Malaysia
Nervous System Diseases
Horses
India
Monoclonal Antibodies
Infection

Keywords

  • G glycoprotein
  • Hendra virus
  • Horse
  • Monoclonal antibody
  • Nipah virus
  • Vaccine

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Broder, C. C., Xu, K., Nikolov, D. B., Zhu, Z., Dimitrov, D. S., Middleton, D., ... Wang, L. F. (2013). A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Research, 100(1), 8-13. https://doi.org/10.1016/j.antiviral.2013.06.012

A treatment for and vaccine against the deadly Hendra and Nipah viruses. / Broder, Christopher C.; Xu, Kai; Nikolov, Dimitar B.; Zhu, Zhongyu; Dimitrov, Dimiter S.; Middleton, Deborah; Pallister, Jackie; Geisbert, Thomas; Bossart, Katharine N.; Wang, Lin Fa.

In: Antiviral Research, Vol. 100, No. 1, 2013, p. 8-13.

Research output: Contribution to journalArticle

Broder, CC, Xu, K, Nikolov, DB, Zhu, Z, Dimitrov, DS, Middleton, D, Pallister, J, Geisbert, T, Bossart, KN & Wang, LF 2013, 'A treatment for and vaccine against the deadly Hendra and Nipah viruses', Antiviral Research, vol. 100, no. 1, pp. 8-13. https://doi.org/10.1016/j.antiviral.2013.06.012
Broder, Christopher C. ; Xu, Kai ; Nikolov, Dimitar B. ; Zhu, Zhongyu ; Dimitrov, Dimiter S. ; Middleton, Deborah ; Pallister, Jackie ; Geisbert, Thomas ; Bossart, Katharine N. ; Wang, Lin Fa. / A treatment for and vaccine against the deadly Hendra and Nipah viruses. In: Antiviral Research. 2013 ; Vol. 100, No. 1. pp. 8-13.
@article{87a5bff98e874bc99852ad3ceaeda442,
title = "A treatment for and vaccine against the deadly Hendra and Nipah viruses",
abstract = "Hendra virus and Nipah virus are bat-borne paramyxoviruses that are the prototypic members of the genus Henipavirus. The henipaviruses emerged in the 1990s, spilling over from their natural bat hosts and causing serious disease outbreaks in humans and livestock. Hendra virus emerged in Australia and since 1994 there have been 7 human infections with 4 case fatalities. Nipah virus first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India. In total, there have been an estimated 582 human cases of Nipah virus and of these, 54{\%} were fatal. Their broad species tropism and ability to cause fatal respiratory and/or neurologic disease in humans and animals make them important transboundary biological threats. Recent experimental findings in animals have demonstrated that a human monoclonal antibody targeting the viral G glycoprotein is an effective post-exposure treatment against Hendra and Nipah virus infection. In addition, a subunit vaccine based on the G glycoprotein of Hendra virus affords protection against Hendra and Nipah virus challenge. The vaccine has been developed for use in horses in Australia and is the first vaccine against a Biosafety Level-4 (BSL-4) agent to be licensed and commercially deployed. Together, these advances offer viable approaches to address Hendra and Nipah virus infection of livestock and people.",
keywords = "G glycoprotein, Hendra virus, Horse, Monoclonal antibody, Nipah virus, Vaccine",
author = "Broder, {Christopher C.} and Kai Xu and Nikolov, {Dimitar B.} and Zhongyu Zhu and Dimitrov, {Dimiter S.} and Deborah Middleton and Jackie Pallister and Thomas Geisbert and Bossart, {Katharine N.} and Wang, {Lin Fa}",
year = "2013",
doi = "10.1016/j.antiviral.2013.06.012",
language = "English (US)",
volume = "100",
pages = "8--13",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A treatment for and vaccine against the deadly Hendra and Nipah viruses

AU - Broder, Christopher C.

AU - Xu, Kai

AU - Nikolov, Dimitar B.

AU - Zhu, Zhongyu

AU - Dimitrov, Dimiter S.

AU - Middleton, Deborah

AU - Pallister, Jackie

AU - Geisbert, Thomas

AU - Bossart, Katharine N.

AU - Wang, Lin Fa

PY - 2013

Y1 - 2013

N2 - Hendra virus and Nipah virus are bat-borne paramyxoviruses that are the prototypic members of the genus Henipavirus. The henipaviruses emerged in the 1990s, spilling over from their natural bat hosts and causing serious disease outbreaks in humans and livestock. Hendra virus emerged in Australia and since 1994 there have been 7 human infections with 4 case fatalities. Nipah virus first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India. In total, there have been an estimated 582 human cases of Nipah virus and of these, 54% were fatal. Their broad species tropism and ability to cause fatal respiratory and/or neurologic disease in humans and animals make them important transboundary biological threats. Recent experimental findings in animals have demonstrated that a human monoclonal antibody targeting the viral G glycoprotein is an effective post-exposure treatment against Hendra and Nipah virus infection. In addition, a subunit vaccine based on the G glycoprotein of Hendra virus affords protection against Hendra and Nipah virus challenge. The vaccine has been developed for use in horses in Australia and is the first vaccine against a Biosafety Level-4 (BSL-4) agent to be licensed and commercially deployed. Together, these advances offer viable approaches to address Hendra and Nipah virus infection of livestock and people.

AB - Hendra virus and Nipah virus are bat-borne paramyxoviruses that are the prototypic members of the genus Henipavirus. The henipaviruses emerged in the 1990s, spilling over from their natural bat hosts and causing serious disease outbreaks in humans and livestock. Hendra virus emerged in Australia and since 1994 there have been 7 human infections with 4 case fatalities. Nipah virus first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India. In total, there have been an estimated 582 human cases of Nipah virus and of these, 54% were fatal. Their broad species tropism and ability to cause fatal respiratory and/or neurologic disease in humans and animals make them important transboundary biological threats. Recent experimental findings in animals have demonstrated that a human monoclonal antibody targeting the viral G glycoprotein is an effective post-exposure treatment against Hendra and Nipah virus infection. In addition, a subunit vaccine based on the G glycoprotein of Hendra virus affords protection against Hendra and Nipah virus challenge. The vaccine has been developed for use in horses in Australia and is the first vaccine against a Biosafety Level-4 (BSL-4) agent to be licensed and commercially deployed. Together, these advances offer viable approaches to address Hendra and Nipah virus infection of livestock and people.

KW - G glycoprotein

KW - Hendra virus

KW - Horse

KW - Monoclonal antibody

KW - Nipah virus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84881141420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881141420&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2013.06.012

DO - 10.1016/j.antiviral.2013.06.012

M3 - Article

C2 - 23838047

AN - SCOPUS:84881141420

VL - 100

SP - 8

EP - 13

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -